COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Acceptability Study of Vaginal Films for HIV Prevention (FACE)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01231763
Recruitment Status : Completed
First Posted : November 1, 2010
Last Update Posted : February 9, 2011
Doris Duke Charitable Foundation
Information provided by:
University of Pittsburgh

Brief Summary:

This study is being done to find out what women would want in a film vaginal product for human immunodeficiency virus (HIV) prevention, especially what it should look like and how to apply it.

The investigators hypothesize that women will prefer a smooth, clear, and rectangular quick-dissolve vaginal film for HIV prevention over a textured, opaque, square quick-dissolve vaginal film.

Condition or disease Intervention/treatment
HIV Infections Anti-Infective Agents Other: No intervention (not applicable)

Detailed Description:

The lives of 25 million people have ended due to HIV-related causes since the start of the AIDS epidemic in 1981 (1). Each year, AIDS continues to claim the lives of millions of people, with an estimated two million deaths worldwide in 2008 (2). Heterosexual transmission of HIV accounts for the majority of new infections and disproportionately affects women both in the United States and globally (2, 3). There is an urgent need for agents to prevent the sexual transmission of HIV, particularly agents that may be controlled by women.

Quick dissolve films such as Listerene® Breath Strips have been developed for inexpensive delivery of drugs and vitamins. As products for HIV prevention, quick dissolve films offer a host of potential advantages including low cost, control by the receptive partner, discreet and applicator-free use, low mess, portability, easy storage, stability, targeting to site of exposure, reduction of systemic toxicity by bypassing first-pass metabolism, and the incorporation of multiple active microbicidal compounds (4, 5).

In the course of developing agents for HIV prevention, determination of valued characteristics is important for product refinement and for enhancement of future use likelihood. Knowledge regarding acceptability can also inform product promotion and educational campaigns (6).

Layout table for study information
Study Type : Observational
Actual Enrollment : 84 participants
Observational Model: Cohort
Time Perspective: Cross-Sectional
Official Title: Film Acceptability Characterization and Evaluation
Study Start Date : November 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : February 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Group/Cohort Intervention/treatment
Healthy volunteers Other: No intervention (not applicable)
No intervention (not applicable)

Primary Outcome Measures :
  1. Preferred physical characteristics of a vaginal film product [ Time Frame: One visit lasting two hours ]
    Preferred texture, shape, size, and appearance of a vaginal film product via focus group discussion and questionnaires

Secondary Outcome Measures :
  1. Valued vaginal product characteristics [ Time Frame: One visit lasting two hours ]
    Desired characteristics of vaginal products such as lubrication, prescription status, and contraceptive function via focus group discussion and questionnaires

  2. Impressions regarding vaginal films [ Time Frame: One visit lasting two hours ]
    Impressions about vaginal films such as ease of use, comfort, and effect on sexual pleasure via focus group discussion and questionnaires

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years to 30 Years   (Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   Yes
Sampling Method:   Non-Probability Sample
Study Population
Women aged 18-30 years from the Pittsburgh, Pennsylvania area who express interest in the study. Enrollment is expected to achieve racial and ethnic demographics representative of Allegheny County, Pennsylvania in terms of approximately 0.2 percent American Indian and Alaska Native, 2.5 percent Asian, and 1.5 percent Hispanic or Latino (7). Allegheny County is 82.8 percent white and 13.2 percent black or African American (7). For enrollment in this study, we would like to achieve at least 40 percent black or African American in order to collect a more diverse set of film microbicide preferences. The remainder of enrollment is expected to be white.

Inclusion Criteria:

  • Female 18-30 years old at time of enrollment
  • Able to provide written informed consent

Exclusion Criteria:

  • Not sexually active, defined as no vaginal sex at any time in the past year
  • Pregnant by self-report

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01231763

Layout table for location information
United States, Pennsylvania
Magee-Womens Hospital of UPMC
Pittsburgh, Pennsylvania, United States, 15213
Magee-Womens Research Institute
Pittsburgh, Pennsylvania, United States, 15213
Sponsors and Collaborators
University of Pittsburgh
Doris Duke Charitable Foundation
Layout table for investigator information
Principal Investigator: Sharon Hillier, PhD University of Pittsburgh
Layout table for additonal information
Responsible Party: Sharon Hillier, PhD, University of Pittsburgh Identifier: NCT01231763    
Other Study ID Numbers: PRO10080621 (UPittsburgh IRB#)
First Posted: November 1, 2010    Key Record Dates
Last Update Posted: February 9, 2011
Last Verified: February 2011
Keywords provided by University of Pittsburgh:
HIV prevention
Vaginal film
Administration, intravaginal
Additional relevant MeSH terms:
Layout table for MeSH terms
HIV Infections
Lentivirus Infections
Retroviridae Infections
RNA Virus Infections
Virus Diseases
Sexually Transmitted Diseases, Viral
Sexually Transmitted Diseases
Immunologic Deficiency Syndromes
Immune System Diseases